RAIR Health Limited
Home
About Us
Team
Media and Events
Solutions
  • Imageomics
  • Oculair™
Contact Us
Scientific Advisors
RAIR Health Limited
Home
About Us
Team
Media and Events
Solutions
  • Imageomics
  • Oculair™
Contact Us
Scientific Advisors
More
  • Home
  • About Us
  • Team
  • Media and Events
  • Solutions
    • Imageomics
    • Oculair™
  • Contact Us
  • Scientific Advisors
  • Home
  • About Us
  • Team
  • Media and Events
  • Solutions
    • Imageomics
    • Oculair™
  • Contact Us
  • Scientific Advisors

The Imageomics Company

The Imageomics CompanyThe Imageomics CompanyThe Imageomics CompanyThe Imageomics Company

Applying biomedical knowledge management tools and AI to real-world data and images to extract valuable clinical insights

Find Out More

The Imageomics Company

The Imageomics CompanyThe Imageomics CompanyThe Imageomics CompanyThe Imageomics Company

Applying biomedical knowledge management tools and AI to real-world data and images to extract valuable clinical insights

Find Out More

Latest News

August 15, 2022:  RAIR Health Limited today announces it has joined the PathLAKE consortium as an Associate Member. RAIR’s expertise in the application of AI-driven biomedical knowledge systems and feature extraction is expected to  help PathLAKE apply AI to real-world data and to improve patient outcomes.

For More News and Events

Digital health developers spend 60-80% of their time on data access and pre-processing tasks, at significant cost to the project. RAIR provides a single point of access to proprietary, AI-ready datasets, tools and expertise, making projects faster, cheaper and better.

Data and artificial intelligence provide opportunities to transform the efficacy and efficiency of the healthcare industry....


...but the data required to test/train algorithms is highly siloed and scattered across dozens of institutions/systems (pharmacies, hospitals, imaging and diagnostic test systems etc.), making it extremely expensive and time consuming to collect and prepare the data.  Therefore data fragmentation presently represents a material  impediment to the realisation of the enormous promise from the use of AI in healthcare.


RAIR is focussed on solving access, fragmentation and interlinking of diverse datasets, in order to facilitate new areas of medical research; to  help providers to refine the passage of patients through their systems; and to help deliver personalised medicine, ensuring that, in future, the right medicine is delivered to the right patient at the right time.


RAIR extracts and  organises a wide variety of different data types including publicly available genomic data, clinical notes, medical images, test results and more.   RAIR undertakes the laborious job of ironing out the wrinkles in the data, so that it can be used by researchers, before making the data available in a form and framework which satisfies both the needs of the scientists and the highest standards of information governance.  Thereafter, RAIR's state-of-the-art data science solution (Oculair™)  helps researchers to identify patterns of disease,  progression, success and failure, which are often buried deep within the data, and to extract knowledge and insights to help refine patients pathways and support the development of novel new products and services. 


RAIR is focused on those chronic diseases which manifest in the eye which, aside from ophthalmology, include large therapeutic areas such as cardiovascular, rheumatological and neurological disease.

Oculair™ is a best-in-class, scalable, serverless, biomedical knowledge management system

The UK is one of the best, if not the best places to conduct data-driven research.  The NHS holds cradle-to-grave (longitudinal) medical records on every citizen and the data is generally held in electronic form and of a high standard.


RAIR has access to highly-sought NHS real world data sourced through a non-exclusive data license agreement.  The data  currently reflects a population of <1m people generating data on over 100k new episodes a year.


Oculair™ is  a best-in-class, scalable, serverless, biomedical knowledge system which provides researchers with the opportunity to visualise, understand and to extract insights from complex biological systems comprising scientific (genomic, drug and protein systems)  real world clinical data (NHS) and other contextualising (environmental, social etc.) data  sets.  


Knowledge of hidden patterns and associations helps researchers to redesign and improve patient pathways; to identify new uses for approved drugs,  to stratify patient populations and identify clinical endpoints to make clinical trials more efficient; to identify relative value for money between new/existing products and pathways;  to identify biomarkers that may help diagnose patients sooner; and to predict drug response or adverse events enabling personalised treatment.



Learn more

Our Technology Partners


With offices at tech centres across Europe, Future Processing has expertise in the field of medical software development;  big data engineering and machine/deep learning with particular specialisation in the development of advanced medical and image segmentation algorithms.

RAIR is proud to be an Associate Member of the PathLAKE consortium which comprises some of the nation’s leading digital and computational innovators from NHS and academia. 

Vaticle's Type DB is the knowledge graph engine used to organise and interrogate very large, complex networks of data. Type DB provides the knowledge foundation for cognitive and intelligent (e.g. AI) systems, by providing an intelligent language for modelling, transactions and analytics. 

Facts and Figures

...the cost of partial sight and blindness to the UK economy each year

...the number UK patients uneccessarily losing their vision each month due to delays in treatment.

...the number UK patients uneccessarily losing their vision each month due to delays in treatment.

 It is estimated that the annual economic burden of vision loss and vision disorders in adults costs the UK economy around £22 billion per year and in the US economy $ 139 billion.  


RAIR's medical retina data lake includes two of the largest ophthalmic indications: diabetic macular oedema and neovascular (or “Wet”) age-related macular degeneration (nAMD).  





...the number UK patients uneccessarily losing their vision each month due to delays in treatment.

...the number UK patients uneccessarily losing their vision each month due to delays in treatment.

...the number UK patients uneccessarily losing their vision each month due to delays in treatment.

The increased incidence of chronic eye disease, including diabetes and nAMD, has placed the healthcare system under significant financial and clinical pressure:   


Diabetic macular oedema (DMO) and Age-related macular degeneration (AMD) account for 20% of the 1.8m new NHS presentations and 8m consultations each year and represent the major

The increased incidence of chronic eye disease, including diabetes and nAMD, has placed the healthcare system under significant financial and clinical pressure:   


Diabetic macular oedema (DMO) and Age-related macular degeneration (AMD) account for 20% of the 1.8m new NHS presentations and 8m consultations each year and represent the major causes of vision loss.


However, in the UK:

67% of eye units are using locums;

85% of units are reliant on waiting list initiatives to clear backlogs and 4.2m patients are waiting to start treatment.

...percentage of patients who do not get optimal outcomes from the current standard of care

...the number UK patients uneccessarily losing their vision each month due to delays in treatment.

...percentage of patients who do not get optimal outcomes from the current standard of care


 Anti-VEGF therapy is the first-line drug treatment for DMO and AMD.  However, while far more effective than the alternatives, anti-VEGF drugs are ineffective or partially effective in 41-64% of treated patients, and in 4.5-8.8% of treated patients their eyesight actually deteriorates.


Nonetheless, anti-VEGF therapies constituted the 2nd a


 Anti-VEGF therapy is the first-line drug treatment for DMO and AMD.  However, while far more effective than the alternatives, anti-VEGF drugs are ineffective or partially effective in 41-64% of treated patients, and in 4.5-8.8% of treated patients their eyesight actually deteriorates.


Nonetheless, anti-VEGF therapies constituted the 2nd and 8th highest individual drug costs across the entire  NHS in 2018 and, in the US, anti-VEGF therapy  accounts for c.12% of Medicare Part B drug spending.  


The burden of administering frequent intravitreal injections on healthcare human resources is also considerable, with each patient requiring several treatments a year, administered by a trained practitioner, most often a consultant ophthalmologist. 




  • Privacy Policy

RAIR Health Limited

Health Foundry, Canterbury House, 1 Royal St, London, SE1 7LL

020 7924 2345

Copyright © 2021 RAIR Health Limited - All Rights Reserved.

This website uses cookies.

  

What are cookies and how do they work?

“Cookies” are text-only pieces of information that a website transfers to an individual’s hard drive or other website-browsing equipment for record-keeping purposes. Cookies allow the website to remember important information that will make your use of the site more convenient. A cookie will typically contain the name of the domain from which the cookie has come, the “lifetime” of the cookie, and a randomly generated unique number or other value. Like most websites, we use different categories of cookies for a variety of purposes in order to improve your online experience.

Depending on the purpose, we use session cookies, which are temporary cookies that remain in the cookie file of your browser until you leave the site, and persistent cookies, which remain in the cookie file of your browser for 20 years.


What are the categories of cookies?

Cookies can be categorised, following the International Chamber of Commerce guide, as follows:


Strictly necessary cookies

‘Strictly necessary cookies’ tend to be session cookies which are deleted at the end of the browser session.

Accepting these cookies is a condition of using the website, so if you prevent these cookies, we can’t guarantee how our website will perform during your visit.


Performance Cookies

‘Performance cookies’ collect information about how you use our website such as which pages you visit and if you experience any errors. These cookies don’t collect any information that could identify you – all the information is collected on an anonymous aggregate basis and is only used to help us improve how our website works, understand what interests our users and measure the effectiveness of our advertising. They also enable us to track the total number of visitors to our site. Most performance cookies tend to be session cookies which are deleted at the end of the browser session.

In some cases, some of these cookies are managed for us by third parties, but we don’t allow the third party to use the cookies for any purpose other than those listed above. Some of these third-party performance cookies are persistent cookies.


Functionality Cookies

Functionality cookies, by their very nature, are persistent cookies so that we remember your computer when you return to our website.

Some of these cookies are managed for us by third parties – where this is the case, we don’t allow the third party to use the cookies for any purpose other than those listed above.


How can I block and/or delete cookies?

Use the options in your web browser if you do not wish to receive a cookie or if you wish to set your browser to notify you when you receive a cookie. You can easily delete any cookies that have been installed in the cookie folder of your browser.

Accept